Navigation Links
Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs
Date:9/9/2009

Vitro Biopharma announces commercial availability of "Tools for Stem Cell and Drug DevelopmentTM" including products for use in cancer stem cell research. Vitro also owns proprietary technology for cancer stem cell therapy and this technology complements newly developed drugs that block a biological pathway (hedge hog) that drives the proliferation of cancer stem cells.

Golden, CO (PRWEB) September 9, 2009 -- Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

Cancer stem cells are thought to generate cancerous tumors, and while some of these tumor cells are destroyed by chemotherapy and radiation, cancer stem cells resist these treatments causing recurrences and metastasis of cancer following standard therapy. For example, glioblastoma tumors underlying Senator Kennedy's brain cancer may arise from cancer stem cells that resist conventional treatments. Additional research shows that certain adult stem cells migrate to cancer stem cells and may be used to carry toxic agents to selectively eradicate cancer stem cells thereby providing novel cellular therapy specifically targeted to cancer-causing cells. Further development of Vitro's stem cell therapy may allow treatment of presently untreatable cancer and also have more widespread applications to prevention and treatment of cancer.

Vitro's proprietary stem cell technology and products, now subject to pending patent protection, may lead to novel cell therapy for cancer. The Company is pursuing suitable strategic partners to commercialize these novel therapeutic products. Furthermore, the Company has also commercialized various modified stem cell lines and related products to support cancer stem cell research including the development of new methods to target the selective eradication of cancer stem cells, which is essential to therapeutic efficacy. These products and other tools for use in stem cell research are now commercially available (http://www.vitrobiopharma.com/).

The hedge hog pathway drives the proliferation of cancer stem cells and has been a target for drug development for sometime, based on earlier work with the plant-derived substance, cyclopamine, a specific blocking agent of the hedge hog pathway. Novel hedge hog drugs have been developed by several pharmaceutical companies and new reports are showing effectiveness in treating cancer. Hedge hog blocking drugs are known to kill cancer stem cells and this mechanism may underlie their effectiveness in cancer treatment. Vitro's novel stem cell mediated cancer therapy complements hedge hog drugs by targeted destruction of cancer stem cells.

Dr. Rice, a member of Vitro's SAB and a University of Colorado cancer researcher said, "Cellular-mediated destruction of cancer stem cells represents a promising new avenue for the development of effective treatments that specifically target cancer stem cells. Vitro has developed an exciting portfolio of products to advance research in this field, which is one of the few approaches to show promise against intractable cancers such as most forms of brain cancer. Additionally, Vitro's patent pending technology for cancer therapy represents an exciting and novel approach to the selective eradication of cancer stem cells that could usher in new promise in the fight against cancer."

About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG; http://www.vitrobiopharma.com), known for "Harnessing the Power of Cells" owns US patents for production of the fertility drug, FSH, immortalization of cells, and adult stem cells. The Company also owns a pending US patent regarding stem cell-based cancer treatments and is continuously developing newly patentable cell lines and technologies. Vitro recently established a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. The current focus is "Tools for Stem Cell and Drug Development™", a series of commercially available products for use in stem cell research and drug development targeting human mesenchymal stem cells, induced pluripotent stem cells and stem cell-based cancer research. In addition, Vitro's stem cell technology has shown promise for development of stem cell therapy for diabetes and cancer.

Safe Harbor Statement:
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Dr. James Musick
Chief Executive Officer
Vitro Diagnostics, Inc.
(303) 999-2130

MEDIA CONTACT:
Sandra Kay Helsel, Ph.D.
SK Helsel & Associates
Office: 520-325-4636
Cell: 520-390-8184

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2848194.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: